ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / WGS / insiders
ADUS (74) TDOC (55) PRVA (53) AVAH (65) ⌘ Pro Terminal β†’

GeneDx Holdings Corp. (Class A) (WGS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$69.06 -2.76% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $68.59

GeneDx Holdings Corp. (Class A) (WGS) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record Warning: Scores below 50 (47/100 Β· D) historically underperformed SPY in 71% of rolling 90-day windows β†’
ROARABLE D β€’ SELL / AVOID Cap $2.06B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on WGS Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is WGS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, GeneDx Holdings Corp. (Class A) (NASDAQ: WGS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $69.06 (-2.76% 1D, market cap $2.06B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 6/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does WGS compare to ADUS and TDOC in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Nursing Services), WGS carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 69.7%, and ROIC of -4.1%. By comparison, ADUS (Addus HomeCare Corporation) holds a B grade (74/100 RQD, P/E 24.2x, ROIC 9.1%, cap $2.34B) and TDOC (Teladoc Health Inc.) posts a D+ grade (55/100 RQD, P/E N/A, ROIC -17.0%, cap $1.55B). Among the 5-stock peer group, ADUS leads on earnings multiple (24.2x) while AVAH leads on capital efficiency (15.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for WGS?
β–Ό

Per WGS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818331), GeneDx Holdings Corp. (Class A) generated $427.5M in revenue (+40.0% YoY), -$21.0M in net income, and $14.3M in free cash flow against $523.7M in total assets and $48.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $68.58 (-0.69%)🧬 Dilution Drag (+1.64% YoY Shares)βš™οΈ Cash Engine: 12/20 (C-) β€’ 3.3% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (47/100 Β· D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510047
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- Β· Rk D+
Cash (12)Whales (7)SEC (14)Macro (8)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
$179 Bull$66 Base$51 Bear
πŸ“¬ FREE WGS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for WGS)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
πŸ” WHY WGS SCORES 47/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (30% of score)

Altman Z-Score 3.32 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 8/9

β–² #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 3.3% FCF Margin ($14.3M FCF) & 69.7% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)

Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
39
Grade E$64.96+5.8% Next Q
Q2 (-2Q)
42
Grade D$68.74-8.7% Next Q
Q3 (-1Q)
44
Grade D$62.74+10.1% Next Q
Current
47
Grade D$69.06-5.9% Hist 90D Ξ±
Trajectory: E (39) β†’ D (47)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a WGS Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While WGS currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($78.40) and Max Pain ($72.51) forces dealer call-delta covering toward $179.41.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $WGSβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œWGS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

WGS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (WGS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on WGS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring WGS)

  • βœ“Walkthrough of WGS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
WGS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.66%πŸ“ HORIZONTAL RANGE
2026-11-03O $71.02H $71.02L $69.06C $69.06VOL 886.2K
RES: $125.2SUP: $54.67SMA50: $78.40SMA200: $71.54
$114.4$92.11$69.84$47.57$25.30RES $125.2SUP $54.67$69.062026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WGS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ WGS Butterfly Map β†’ + Track WGS β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +40.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on WGS today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for WGS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for WGS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WGS)

Health Care Rank #304 of 1016 βš”οΈ ADUS vs WGS Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (WGS vs. ADUS, TDOC, PRVA, AVAH)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, GeneDx Holdings Corp. (Class A) (WGS) ranks #304 by composite RQD confidence (47/100, grade D) and #249 by equity capitalization ($2.06B). Within this direct 5-issuer industry benchmark cohort, ADUS leads on earnings valuation at 24.2x trailing P/E, while AVAH leads on capital efficiency and profitability with 15.7% ROIC and 33.3% gross margin. ADUS currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with WGS at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
WGS ACTIVE
GeneDx Holdings Corp. (Class A)
D 47/100 β€” 69.7% -4.1% -2.76% $2.06B Benchmark Subject
ADUS
Addus HomeCare Corporation
B 74/100 24.2x 32.5% 9.1% +0.97% $2.34B /adus-vs-wgs β†’
TDOC
Teladoc Health Inc.
D+ 55/100 β€” β€” -17.0% -2.52% $1.55B /tdoc-vs-wgs β†’
PRVA
Privia Health Group Inc.
D+ 53/100 122.6x β€” 10.5% -2.34% $2.74B /prva-vs-wgs β†’
AVAH
Aveanna Healthcare Holdings Inc.
C 65/100 β€” 33.3% 15.7% -0.75% $2.87B /avah-vs-wgs β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001818331

In its most recent audited fiscal period (FY2025, filed 2025-12-31), GeneDx Holdings Corp. (Class A) (WGS) reported GAAP revenue of $427.5M (+40.0% vs. FY2024 revenue of $305.4M , and +111.1% cumulative change since FY2023) , GAAP net income of -$21.0M, operating cash flow of $33.3M, and free cash flow of $14.3M (+142.0% YoY). On the balance sheet, WGS closed FY2025 with $523.7M in total assets against $48.2M in total debt (Altman Z-Score: 3.32, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $427.5M -$21.0M $33.3M $14.3M $523.7M $48.2M
FY2024 (FY) 2024-12-31 $305.4M -$52.3M -$28.5M -$34.0M $419.4M $51.9M
FY2023 (FY) 2023-12-31 $202.6M -$175.8M -$180.1M -$180.1M β€” β€”

3. WGS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WGS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, GeneDx Holdings Corp. (Class A) (NASDAQ: WGS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $69.06 (-2.76% 1D, market cap $2.06B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 6/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

How does WGS compare to ADUS and TDOC in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), WGS carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 69.7%, and ROIC of -4.1%. By comparison, ADUS (Addus HomeCare Corporation) holds a B grade (74/100 RQD, P/E 24.2x, ROIC 9.1%, cap $2.34B) and TDOC (Teladoc Health Inc.) posts a D+ grade (55/100 RQD, P/E N/A, ROIC -17.0%, cap $1.55B). Among the 5-stock peer group, ADUS leads on earnings multiple (24.2x) while AVAH leads on capital efficiency (15.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for WGS?

Per WGS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818331), GeneDx Holdings Corp. (Class A) generated $427.5M in revenue (+40.0% YoY), -$21.0M in net income, and $14.3M in free cash flow against $523.7M in total assets and $48.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is WGS trading relative to its 50-day, 200-day, and 52-week technical levels?

WGS last traded at $69.06 (-2.76% on volume of 886,215 shares), positioning the stock -11.91% below its 50-day simple moving average ($78.40) and -3.47% below its 200-day simple moving average ($71.54). Across its 52-week range of $32.21 to $170.87, WGS sits at the 26.6% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($60.43 to $77.69).

WGS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Are WGS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies WGS leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: WGS RQD Cockpit WGS 12M Forecast WGS Earnings & Move WGS Dividends & DRIP WGS Insiders & 13F WGS Whale Options WGS Profit Sankey WGS News & Why
ROARABLE RATING BRIEF β€’ RQD 47/100 (D) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

WGS β€” GeneDx Holdings Corp. (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:26:39Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD Score is 47 out of 100, a grade of D, labeled "Roarable Sell β€” Underperform / Distribution Warning" (per the Roarable RQD rating). The five pillars break down as follows:

  • Fundamental Cash Engine (12/20): Return on invested capital is -4.1% and FCF yield is 0.67% (per the Roarable RQD rating and market data). For a prospective investor, this means the business is not currently generating returns above its cost of capital, and the cash yield on the current market value is thin. Upside from this pillar would depend on operating improvement that the source data does not yet show.
  • Whale 13F Flow (7/20): Institutional accumulation and options positioning scored low (per the Roarable RQD rating). The score signals limited evidence of sustained large-holder conviction in the source data.
  • Insider Conviction (6/20): SEC Form 4 and Congressional PTR cluster flow scored low (per the Roarable RQD rating). This is a weak signal of insider confidence in the current price level.
  • Macro Regime Fit (8/20): Beta is 1.0 (per market data), and the score reflects sector sensitivity (per the Roarable RQD rating). The stock moves in line with the broader market, so macro conditions neither clearly help nor clearly hurt it on this measure.
  • Forensic Balance Sheet (14/20): Altman Z-Score is 3.32, Piotroski F-Score is 8 of 9, and Debt/Equity is 0.16 (per the Roarable RQD rating). This is the strongest pillar and suggests the balance sheet is not the primary near-term risk.

Investor implication: the balance sheet is the strongest part of the picture, while profitability, cash generation, and insider/institutional signals are weak. Upside drivers would need to come from operating margin recovery toward breakeven and beyond; the source data does not establish that path. Valuation tradeoffs are significant because earnings-based multiples are not available in the source data, so the price cannot be checked against earnings here. The 52-week range of $32.21 to $170.87 (per market data) shows very wide price dispersion, which reflects high volatility in expectations.

Business

GeneDx Holdings Corp. (Class A) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Nursing Services industry (per the company profile). The source data does not describe its specific products, customers, or revenue model. Its reported revenue figures (see Financial Trend) indicate an operating business with growing top-line sales, but the source data does not explain how it earns that revenue. Market capitalization is $2.12B (per market data).

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$427.5M$-13.1M$-21.0MN/A$14.3M$105.0M$48.2M
FY 2024$305.4M$-23.2M$-52.3MN/A$-34.0M$85.2M$51.9M
FY 2023$202.6M$-180.6M$-175.8MN/A$-180.1MN/AN/A

Reported revenue rose from $202.6M in FY 2023 to $427.5M in FY 2025 (per the SEC financials), and operating losses narrowed from $-180.6M to $-13.1M over the same period. Net income was still negative in FY 2025 at $-21.0M, and the gross margin is 69.7% with operating margin at -3.1% and net margin at -4.9% (per market data). ROIC is -4.1% (per market data). The Altman Z-Score is 3.32, the Piotroski F-Score is 8 of 9, and Debt/Equity is 0.16 (per the Roarable RQD rating); the balance sheet appears sound on those measures, with FY 2025 cash of $105.0M against debt of $48.2M (per the SEC financials).

Recent Catalysts & News Wire Analysis

Six news items are listed, all dated within roughly the last 15 hours of the data timestamp and each tagged as a yellow-light market wire item (per the news feed). Headlines include "How Long Can GeneDx Keep Burning Cash?" (Trefis), a GuruFocus item describing the stock as up 4.2% and undervalued with a GF Score of 69/100, and a Simply Wall St forecast piece. The headline question from Trefis is a risk-watch item: it signals that cash burn sustainability is a live investor concern. The GuruFocus headline's undervaluation claim is a third-party assertion and is not independently verified in the source data.

Proprietary signal (per the Butterfly Supply-Chain Graph): a LIQUIDITY_TAILWIND signal rated BULLISH with severity 85, labeled Macro Tailwind Score (85/100). The signal states a 2.36x True Net Liquidity beta and an r of -0.16, and it reports Net Liquidity at $5,745.73B with a -0.64% four-week rate of change and High-Yield OAS up 2 bps. A low r indicates the relationship is weak, so the beta should be treated as a loose estimate rather than a reliable driver.

Open Questions

  • What drives the path from -3.1% operating margin to profitability, and what does management guide to? The source data does not include guidance.
  • How much cash burn remains, and how long does the $105.0M of cash last at FY 2025 burn rates? The Trefis headline raises this question without answering it.
  • What is the source of the FY 2025 FCF of $14.3M, given that net income and operating income were both negative?
  • What is the basis for the 2.36x liquidity beta, given the r of -0.16, and how stable is it over time?
  • What are the current valuation multiples (P/E, EV/EBITDA, forward P/E), which are all unavailable in the source data?

WGS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for GeneDx Holdings Corp. (Class A) (WGS) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to WGS Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

WGS Bull vs. Bear Conversation Board β€” What's Your Call at $69.06?

πŸ‚ 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON WGS 🐻 50% BEARISH CONVICTION
1. Pick Your Side on WGS:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk βš–οΈ DEBATE HOST 🎯 Target: $76.70 (+8.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is WGS (D β€’ RQD 47/100) a Buy at $71.02?

Welcome to the WGS (GeneDx Holdings Corp. (Class A)) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell β€” Underperform / Distribution Warning) in Medical/Nursing Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $53.27 (-25.0%)
Spot @ $71.02

Pump the brakes on WGS β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on WGS, but look at what you are paying: current EV/EBITDA multiples with 69.7% gross margins. Unless GeneDx Holdings Corp. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $87.35 (+23.0%)
Spot @ $71.02

WGS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on WGS, the market is fixating on short-term headline noise in Medical/Nursing Services and ignoring the balance sheet and cash flow trajectory. At $71.02 (52-wk range $32.21 - $170.87), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%